Payment overview · 2025
General Payments
$123.24
4 reported records · 4 companies
Healthcare provider profile · identity verified
Julia E Norem, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FAYETTEVILLE, NC · NPI 1881690402
Verified facts
What the public records show
CMS Open Payments records show Julia E Norem, M.D. received $123.24 in general payments during 2025 across 4 reported records.
Baxter Healthcare accounted for 34.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Baxter Healthcare | Unresolved — no canonical attribution shown | $42.34 | 34.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $38.33 | 31.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.79 | 22.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.78 | 12.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $123.24 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $42.34 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $38.33 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
77 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 509 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 393 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 359 | 100 |
| Gabapentin | Gabapentin | 285 | 67 |
| Lisinopril | Lisinopril | 281 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 277 | 82 |
| Losartan Potassium | Losartan Potassium | 260 | 73 |
| Omeprazole | Omeprazole | 246 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 62 |
| Furosemide | Furosemide | 187 | 46 |
| Metformin Hcl | Metformin Hcl | 184 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 51 |
| Simvastatin | Simvastatin | 181 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 45 |
| Ezetimibe | Ezetimibe | 131 | 33 |
| Potassium Chloride | Potassium Chloride | 118 | 28 |
| Tramadol Hcl | Tramadol Hcl | 112 | 33 |
| Sertraline Hcl | Sertraline Hcl | 106 | 30 |
| Allopurinol | Allopurinol | 92 | 26 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 92 | 92 |
| Nifedipine Er | Nifedipine | 92 | 21 |
| Glipizide Er | Glipizide | 91 | 22 |
| Jardiance | Empagliflozin | 90 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 34 |
| Alprazolam | Alprazolam | 87 | 18 |
| Metformin Hcl Er | Metformin Hcl | 85 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 15 |
| Alendronate Sodium | Alendronate Sodium | 81 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 81 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 25 |
| Atenolol | Atenolol | 79 | 22 |
| Montelukast Sodium | Montelukast Sodium | 79 | 24 |
| Trulicity | Dulaglutide | 77 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 73 | 20 |
| Meloxicam | Meloxicam | 71 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 11 |
| Ozempic | Semaglutide | 64 | 14 |
| Eliquis | Apixaban | 61 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 61 | 18 |
| Carvedilol | Carvedilol | 60 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 15 |
| Januvia | Sitagliptin Phosphate | 50 | 11 |
| Telmisartan | Telmisartan | 50 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 12 |
| Famotidine | Famotidine | 45 | suppressed |
| Torsemide | Torsemide | 45 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Fluconazole | Fluconazole | 42 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 11 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Glipizide | Glipizide | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 16 |
| Valsartan | Valsartan | 37 | 13 |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Nystatin | Nystatin | 36 | 23 |
| Cefdinir | Cefdinir | 35 | 31 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Prednisone | Prednisone | 33 | 17 |
| Trazodone Hcl | Trazodone Hcl | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 30 |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Klor-Con M20 | Potassium Chloride | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 28 |
| Baclofen | Baclofen | 28 | suppressed |
| Felodipine Er | Felodipine | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 13 |
| Rybelsus | Semaglutide | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 19 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $123.24 · 4 records | Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor, JARDIANCE, TZIELD, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error